IntegraGen Announces Additional Financing
Complete the form below to unlock access to ALL audio articles.
The amount raised reinforces investors' confidence in IntegraGen's efforts to develop and market advances in molecular diagnostics and the company's financial performance in the field of genomic services. Building upon an existing strong cash position, these funds will sustain the development of genetic tests in colorectal and liver cancer as well as speed up R&D and commercialization efforts in the field of autism molecular diagnostics.
Bernard Courtieu, Chief Executive Officer of IntegraGen stated "We are extremely satisfied with this capital infusion which was achieved during extremely difficult market conditions. This is a testimonial to investors' confidence in IntegraGen's efforts, specifically those associated with the commercialization of a genetic autism screening test this year in the USA, as well as our progress in the field of oncology biomarkers. Based on our very strong cash position, we will be able to pursue our development efforts with even greater confidence."
